Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan with Cisplatin and Radiotherapy in Esophageal Squamous Cell Carcinoma
NCT06491134Phase 1Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of irinotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Maximum Tolerable Dose at 1 year. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
irinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06491134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491134.